# Tesamorelin

Egrifta · TH9507

https://graded.pl/en/substances/tesamorelin · Checked: Not yet

Preliminary version. The editors have not finished checking this card, and grades may change.

A medicine that raises growth hormone, approved in the US for excess belly fat in adults with HIV. The EU application was withdrawn.

> This site is for information and education only. It does not promote or encourage the use or purchase of the substances described and is not medical advice. Many are not authorised as medicines and their safety has not been established. We sell nothing and have no ties to sellers. For health decisions, consult a doctor.

## Short answers

### Does tesamorelin work?

A medicine that raises growth hormone, approved in the US for excess belly fat in adults with HIV. The EU application was withdrawn. Fat loss: grade B, effect in studies. Fat around the organs in the belly fell about 18% in people with HIV, the approved use. The effect faded after stopping. There are no data on ordinary weight loss.

### Is Tesamorelin legal?

PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. EU: No approval. The application for Egrifta was withdrawn. US: Prescription only. Prescription medicine (Egrifta).

### Is tesamorelin banned in sport?

Banned in sport, WADA 2026.

### Is Tesamorelin safe?

Well known. A US drug label for one use. It warns of cancer risk and raised IGF-1. Studies were in people with HIV.

## What studies show

| | | | |
|---|---|---|---|
| Fat loss | B | Effect in studies | Fat around the organs in the belly fell about 18% in people with HIV, the approved use. The effect faded after stopping. There are no data on ordinary weight loss. |

## Studies we have read

- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. (JAMA 2014; Random groups, n=50) https://pubmed.ncbi.nlm.nih.gov/25038357/
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. (Journal of acquired immune deficiency syndromes (1999) 2010; Random groups, n=404) https://pubmed.ncbi.nlm.nih.gov/20101189/

## Is it legal

- PL: No approval. The European medicines database (EMA) lists no such medicine in Poland (9 October 2026). The Polish register was down, so we could not check it directly. https://www.ema.europa.eu/en/documents/other/article-57-product-data_en.xlsx (Checked: Not yet)
- EU: No approval. The application for Egrifta was withdrawn. https://www.ema.europa.eu/en/medicines/human/EPAR/egrifta (Checked: Not yet)
- US: Prescription only. Prescription medicine (Egrifta). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022505 (Checked: Not yet)

## Doping

Banned in sport, WADA 2026. https://zoek.officielebekendmakingen.nl/trb-2026-25.html

## How much research exists

- Scientific papers: 95
- Studies with random groups: 21
- Registered studies in people: 24
- These are search results. A count shows how much exists, not how good the studies are. 1 Nov 2026.

---
Open data: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/